PACB (PACB)

$1.58
+0.00%
$463M
Market Cap
P/E Ratio
2.40
Beta
Dividend Yield
Piotroski 3/9Altman Z -6.1 DistressBeneish M -5.22 CleanROIC−WACC -69.6%

Quantitative Summary

Deterministic

Below-average fundamentals indicated by Piotroski score of 3/9; Altman Z of -6.1 falls in the academic distress zone.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The fundamental economics of PACB reveal severe distress, characterized by a negative ROIC-WACC spread of -69.6%, indicating that capital allocation is actively destroying value relative to the cost of equity. This deterioration stems from an inability to generate bottom-line returns, evidenced by net margins collapsing to -341.5% despite maintaining gross margins at 28.6%. The DuPont decomposition implicitly highlights a failure in profitability rather than leverage or turnover issues driving returns. Compounding this fundamental weakness are alarming risk metrics: the Altman Z-Score of -6.1 signals an extremely high probability of bankruptcy, while the Piotroski F-Score of 3/9 confirms significant financial deterioration compared to industry peers. Furthermore, the Beneish M-Score of -5.22 suggests aggressive earnings management or potential accounting irregularities that further erode investor confidence in reported figures.

Valuation analysis is rendered difficult by these negative fundamentals, as traditional multiples lack context when net income is deeply negative and revenue growth remains modest at 3.9% year-over-year. The market appears to be pricing in substantial risk rather than sustainable value creation, given the disconnect between top-line expansion and catastrophic bottom-line erosion. Without a clear path to positive cash flows or margin recovery, any implied growth rate derived from standard DCF models would likely result in negative fair values, suggesting the current price may already reflect extreme pessimism regarding future solvency. The absence of sector data prevents a normalized multiple comparison, but the internal metrics suggest the stock is trading on speculation rather than earnings power.

Risk-adjusted performance indicators underscore the speculative nature of this equity. The annualized Fama-French Alpha of -8.16% indicates that the stock has underperformed its risk-adjusted benchmark significantly over time. Additionally, factor tilts reveal a pronounced exposure to growth risks with an HML score of -0.865 and severe weakness in profitability factors at RMW of -1.296. These data points collectively paint a picture of high volatility driven by fundamental instability rather than disciplined capital allocation or operational efficiency improvements.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

3/9
Piotroski F-Score
Weak — below-average operational and profitability metrics
-6.1
Altman Z-Score
Distress Zone — below 1.8 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.
-5.22
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

28.6%
Gross Margin
-341.5%
Net Margin
-59.9%
ROIC
9.8%
WACC
ROIC − WACC Spread: -69.6%— Negative spread.
+3.9%
Revenue Growth (YoY)
-76.3%
Earnings Growth (YoY)
-118.9M
Free Cash Flow

Balance Sheet Health

145.59x
Debt / Equity
5.15x
Current Ratio
-77.5x
Interest Coverage
-12.06%
FCF Yield
-152.7M
EBITDA

Earnings Surprise History

Q4
✓ Beat
Est: $-0.19
Act: $-0.15
+20.5%
Q3
✓ Beat
Est: $-0.17
Act: $-0.13
+21.5%
Q2
✓ Beat
Est: $-0.14
Act: $-0.12
+15.1%
Q1
✓ Beat
Est: $-0.13
Act: $-0.12
+10.8%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Risk Profile

93.8%
Annual Volatility
0.37
Sharpe (1Y)
-0.26
Sharpe (3Y)
-93.5%
Max Drawdown (3Y)
-97.5%
Max Drawdown (5Y)

Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fama-French 5-Factor Exposure

Academic factor model decomposition — what's really driving this stock's returns.

1.24
Market β
Mkt-RF
+3.169
Size (SMB)
Small-cap tilt
-0.865
Value (HML)
Growth tilt
-1.296
Profit (RMW)
Weak
+0.396
Invest (CMA)
Conservative
Alpha (annual): -8.16%
R²: 28.4%of variance explained by 5 factors

Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.

Fundamentals

-3.7
Forward P/E
PEG Ratio
186.25
Price/Book
6M
Avg Volume
$2.73
52W High
$0.96
52W Low
35%
52W Range Position

Passive Flow Attribution

ETF Draft Effect
$32M
Tracked Passive Exposure
3
ETFs Holding PACB
0.12%
Avg Weight in ETFs
$27B
Total ETF AUM

When investors buy or sell ETFs like ARKG or ARKK, the fund manager is mechanically forced to buy or sell PACB shares regardless of PACB's individual fundamentals. We estimate $32M of passive capital is structurally linked to PACB through 3 tracked ETFs. Passive flows have a limited but growing influence on PACB's daily trading dynamics.

Passive exposure = Σ (ETF AUM × stock weight in ETF) across 3 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.

ETF Contagion Visualizer

Simulate a price drop in PACB to visualize passive redemption contagion across ETFs and collateral stocks.

PACB Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
PACBEpicenterVHTETFARKKETFARKGETFCRSPLow RiskTEMHigh RiskLLYLow RiskTWSTLow RiskTSLALow Risk
PACB Price Drop (%)0

If PACB (PACB) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies CRISPR THERAPEUTICS AG (CRSP) as the most exposed collateral stock, sharing 2 ETFs with PACB. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 3 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

PACB Ownership Dynamics

Passive funds hold 1 in every 12 PACB shares, reducing daily market volatility.

Ticker
PACB
Total Shares
311M
ETF Lock-Up
8.1%
Display Mode
Total Float Impact
8.1%Locked Float

PACB (PACB) exerts measurable gravity on the passive index market, currently representing 1.1% of the ARK Genomic Revolution ETF (ARKG) and 0.3% of the ARK Innovation ETF (ARKK). Across 3 tracked ETFs, approximately 25M shares (8.1% of float) are held by passive funds and rarely trade on the open market. As passive ownership grows, index inclusion changes may increasingly drive price discovery.

Float lock-up computed from 3 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

PACB Institutional Volume Profile

252-day volume distribution by price level. The Point of Control (POC) marks the price where the most institutional volume transacted — an implicit support/resistance floor.

TICKER
PACB
PRICE
$1.58
FLOOR (POC)
$1.27
STRENGTH
High
$1$1$17%$1POC 14%$112%$18%$29%$1.58$27%$2$2$2$2$2$2$2$2$2$3$3$3
Focus Zone
Point of Control (POC) Support (below price) Resistance (above price) Current Price

The highest-volume price zone for PACB over the past year sits near $1.27 (14% of 252-day volume). The current price of $1.58 trades 24.4% above this institutional floor — a sign of upside momentum, though a pullback to the POC zone is a common reversion target. The highly concentrated volume profile (14% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.

Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-05-1129,175$1.41$41,136.75
2026-05-087,592$1.65$12,526.8
2026-05-07180$1.71$307.8
2026-05-04172$1.60$275.2
2026-04-23201$1.71$343.71
2026-04-211,162$1.74$2,021.88
2026-04-16127$1.60$203.2
2026-04-159,814$1.57$15,407.98
2026-04-147,237$1.45$10,493.65
2026-04-13564$1.34$755.76
2026-04-0212,732$1.35$17,188.2
2026-04-0155,443$1.32$73,184.76
2026-03-3120,030$1.26$25,237.8
2026-03-3013,229$1.26$16,668.54
2026-03-2624,205$1.39$33,644.95
2026-03-254,185$1.39$5,817.15
2026-03-242,489$1.39$3,459.71
2026-03-20399$1.40$558.6
2026-03-1985,523$1.33$113,745.59
2026-03-131,418$1.27$1,800.86
2026-03-1253,641$1.35$72,415.35
2026-03-1061,450$1.39$85,415.5
2026-03-0627,078$1.52$41,158.56
2026-03-0445,907$1.52$69,778.64
2026-02-277,200$1.78$12,816
2026-02-19150,860$1.63$245,901.8
2026-02-13207,250$1.84$381,340
2026-02-1230$1.84$55.2
2026-02-057,405$1.95$14,439.75
2026-02-04634,395$2.04$1.3M

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Price Correlations

Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.

Peer252-Day (1Y)126-Day (6M)Direction
WTGXXNaNNaN
BFLY0.5150.638Moderate
TXG0.5000.525Moderate
PSNL0.4910.554Moderate
ILMN0.4740.497Moderate
RXRX0.4520.570Moderate
BEAM0.4300.470Moderate
NTRA0.4080.509Moderate
ADPT0.3990.561Moderate
ABSI0.3940.454Moderate

Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.

Compare PACB to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: 2026-06-02.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.